Praluent vs Losartan: Head-to-Head Efficacy, Safety, and Which One Fits Your Life Stage

Why Women Are Asking About Praluent Versus Losartan

These two drugs rarely compete for the same prescription. They are used here to illustrate how to evaluate different cardiometabolic strategies when your risk profile changes, particularly across perimenopause and menopause, when LDL rises, blood pressure climbs, and cardiovascular risk can roughly double compared with premenopausal years.

Alirocumab (Praluent) targets LDL cholesterol through a completely different mechanism than any statin. Losartan targets the renin-angiotensin-aldosterone system to lower blood pressure and reduce organ damage. A woman with familial hypercholesterolemia and well-controlled blood pressure needs a different conversation than a woman with stage 2 hypertension and modest LDL elevation. Understanding what each drug actually does, what the trial data actually showed in women, and where the evidence gaps remain is what makes this comparison genuinely useful.

What Alirocumab (Praluent) Does and What the Trial Data Actually Shows

Alirocumab is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. By blocking PCSK9, alirocumab allows more LDL receptors to remain on liver cells, pulling more LDL out of circulation. The drug is injected subcutaneously every two weeks at 75 mg or 150 mg, or every four weeks at 300 mg for some indications.

ODYSSEY OUTCOMES: The Key Trial

The ODYSSEY OUTCOMES trial enrolled 18,924 patients who had experienced an acute coronary syndrome in the prior 1 to 12 months and were already on high-intensity or maximum-tolerated statin therapy. Adding alirocumab reduced the composite of coronary heart disease death, non-fatal MI, fatal or non-fatal ischemic stroke, or unstable angina requiring hospitalization by 15% compared with placebo (HR 0.85, 95% CI 0.78 to 0.93, p < 0.001). The absolute risk reduction was 1.6 percentage points over a median follow-up of 2.8 years.

What ODYSSEY OUTCOMES Showed Specifically in Women

Women represented approximately 25% of the ODYSSEY OUTCOMES population, which is a recognized limitation of the cardiovascular outcomes trial literature. Subgroup analyses suggested the relative risk reduction was directionally consistent in women, but these subgroups were not powered to detect statistically significant differences in female participants alone. This is an honest evidence gap: the cardiovascular mortality benefit seen in the full trial cannot be attributed with certainty to women from this dataset.

LDL Reduction Magnitude

In the overall ODYSSEY OUTCOMES population, alirocumab reduced LDL by a mean of 54.7% from baseline at 4 months, with LDL levels reaching approximately 53 mg/dL in the alirocumab group versus 101 mg/dL in the placebo group. Studies across the broader alirocumab clinical program show LDL reductions of 40 to 62% depending on baseline LDL and statin background.

Sex-Specific Pharmacokinetics

Body weight and lean mass affect the pharmacokinetics of biologic drugs. Women on average have lower body weight and different adipose distribution than men, which can influence the volume of distribution for subcutaneous biologics. The prescribing information does not specify dose adjustment by sex, but real-world data from PCSK9 inhibitor registries suggest women may achieve slightly lower trough drug concentrations at the same dose, which has clinical relevance if LDL response is inadequate at 75 mg.

What Losartan Does and What the Trial Data Actually Shows

Losartan blocks the angiotensin II type 1 receptor, preventing angiotensin II from causing vasoconstriction, aldosterone release, and sodium retention. The result is lower blood pressure, reduced cardiac afterload, and renal protection by decreasing intraglomerular pressure.

LIFE Trial: Losartan vs Atenolol

The LIFE (Losartan Intervention For Endpoint Reduction in Hypertension) trial enrolled 9,193 patients aged 55 to 80 with essential hypertension and left ventricular hypertrophy on ECG. Over a mean follow-up of 4.8 years, losartan reduced the composite primary endpoint of cardiovascular death, stroke, or MI by 13% compared with atenolol (HR 0.87, 95% CI 0.77 to 0.98, p = 0.021). The stroke reduction was the dominant driver: a 25% relative risk reduction for stroke compared with atenolol.

Women in LIFE

Women comprised approximately 46% of the LIFE trial population, making it more sex-balanced than most cardiovascular outcome trials of its era. Analyses published from the LIFE dataset found the cardiovascular benefits of losartan vs atenolol were broadly consistent across sexes. This is a relatively strong data point for women compared with much of the hypertension trial literature.

Losartan and Kidney Protection

For women with type 2 diabetes and nephropathy, losartan at 100 mg daily reduced the risk of doubling of serum creatinine, end-stage renal disease, or death by 16% compared with placebo in the RENAAL trial. Diabetic kidney disease disproportionately affects women with long-standing PCOS-related insulin resistance, making this an important consideration.

PCOS and Losartan

Women with polycystic ovary syndrome carry elevated rates of hypertension and early-onset metabolic syndrome. The renin-angiotensin system is upregulated in PCOS, which makes ARBs a mechanistically logical choice when blood pressure control is needed. There are no large randomized trials of losartan specifically in PCOS populations with cardiovascular outcomes, so dosing guidance is extrapolated from general hypertension trials.

Cross-Trial Comparison: Is One Drug "Better"?

No randomized controlled trial has compared alirocumab and losartan head to head, and one almost certainly never will. They treat different conditions through different pathways. Framing one as "better" than the other is a category error, similar to asking whether an antibiotic is better than an antihypertensive.

The question worth answering is: given your specific cardiometabolic risk profile at your current life stage, which drug (or combination) addresses the dominant driver of your cardiovascular risk?

A Life-Stage Risk-Matching Framework for Women

Reproductive years (18-40): In this group, hypertension is less common but not rare, particularly in women with PCOS, obesity, or a history of preeclampsia. Familial hypercholesterolemia can present at any age. If LDL is the dominant driver (familial hypercholesterolemia, post-ACS), alirocumab is the stronger tool. If blood pressure is the issue, losartan works, but this age group requires strict contraception counseling because losartan is contraindicated in pregnancy (see pregnancy section below).

Trying to conceive: Neither drug is appropriate. Both require a washout period before conception. A woman planning pregnancy should discuss switching to a pregnancy-compatible antihypertensive such as labetalol or nifedipine for blood pressure, and stopping lipid-lowering therapy beyond dietary modification.

Perimenopause (typically 45-55): Estrogen decline drives a measurable rise in LDL cholesterol, typically 10 to 15 mg/dL on average during the menopause transition, and accelerates arterial stiffness. Blood pressure tends to rise in this period as well. A woman who was well-managed on a statin alone may suddenly need adjunctive LDL-lowering, making alirocumab more relevant. Simultaneously, new-onset hypertension may emerge, opening a role for losartan. The two drugs address two separate problems that may both appear in the same woman during perimenopause.

Post-menopause (55+): This is the highest-burden group for both elevated LDL and hypertension. Cardiovascular disease is the leading cause of death in women over 65. The ACC/AHA guidelines support PCSK9 inhibitor use for women with atherosclerotic cardiovascular disease (ASCVD) at very high risk who have LDL at or above 70 mg/dL despite maximally tolerated statin. ARBs including losartan remain first-line or second-line for blood pressure control in this group, particularly when diabetes or chronic kidney disease coexists.

Dosing Comparison

| Feature | Alirocumab (Praluent) | Losartan | |---|---|---| | Route | Subcutaneous injection | Oral tablet | | Frequency | Every 2 weeks (75-150 mg) or every 4 weeks (300 mg) | Once daily | | Starting dose | 75 mg every 2 weeks | 25-50 mg once daily | | Maximum dose | 150 mg every 2 weeks | 100 mg once daily | | Dose adjustment in women | Not specified by sex; monitor LDL response | Not specified by sex; start low in elderly women | | Titration | Increase to 150 mg if LDL remains above goal at 4-8 weeks | Titrate to 100 mg based on BP response |

Side-Effect Profiles: What Women Experience

Alirocumab Side Effects

The most common side effects in clinical trials were injection-site reactions (7.2% vs 5.1% for placebo) and nasopharyngitis. Neurocognitive concerns were raised early in the PCSK9 class development; the EBBINGHAUS cognitive substudy of FOURIER found no significant difference in cognitive function between evolocumab (a related PCSK9 inhibitor) and placebo, providing some reassurance, though EBBINGHAUS enrolled predominantly men.

Myalgia is not a class effect of PCSK9 inhibitors, unlike statins. Women who switch to alirocumab because of statin intolerance due to muscle symptoms may find the side-effect profile more tolerable.

Losartan Side Effects

Losartan is generally well tolerated. Unlike ACE inhibitors, it does not cause the persistent dry cough that affects women at roughly twice the rate as men, making it a preferred alternative when an ACE inhibitor causes cough. Hyperkalemia is possible, particularly in women with advanced CKD or those taking potassium-sparing diuretics. Dizziness on standing is more common in older women who are also volume-depleted.

Angioedema is rare but can occur with ARBs; women who have had ACE inhibitor-associated angioedema should use losartan with caution.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

Both drugs are contraindicated in pregnancy. This is not a nuance. It is a firm clinical directive.

Losartan in pregnancy: Losartan carries an FDA Pregnancy Category D (second and third trimester) classification. Use during the second or third trimester is associated with fetal renal dysgenesis, oligohydramnios, neonatal renal failure, skull hypoplasia, and fetal death. Any woman of reproductive potential taking losartan must use reliable contraception. If pregnancy is discovered while taking losartan, the drug should be stopped immediately and an obstetric provider consulted.

Alirocumab in pregnancy: The FDA prescribing information states there are insufficient human data to evaluate the drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal studies used doses that do not adequately reflect human exposure. Given the absence of safety data and the biological plausibility of harm from modifying PCSK9 during fetal development, alirocumab should be stopped before a planned pregnancy. The half-life of alirocumab is approximately 17 to 20 days, so discontinuation at least 5 half-lives (roughly 3 to 4 months) before planned conception is a reasonable precaution, though no firm guidance exists from ACOG or the manufacturer.

Lactation: Neither drug has adequate data on breast milk transfer. The molecular weight of alirocumab (approximately 146 kDa) makes significant transfer into mature breast milk unlikely, but this is theoretical reasoning, not measured human data. Losartan and its active metabolite EXP-3174 have not been adequately studied in lactating women. Given the availability of pregnancy-compatible antihypertensives, most clinicians would advise stopping losartan during breastfeeding and switching to labetalol or nifedipine if blood pressure control is needed.

Contraception counseling: Any woman of reproductive potential on either drug who is not planning pregnancy should use reliable contraception. This is especially relevant during perimenopause, where women sometimes underestimate residual fertility in the years before the final menstrual period.

Who Is Each Drug Right For: A Life-Stage Guide

Alirocumab Is the Stronger Choice When:

• You have established ASCVD (prior MI, stroke, peripheral artery disease) and LDL remains at or above 70 mg/dL on maximum statin
• You have familial hypercholesterolemia with LDL above 100 mg/dL despite statin
• You are statin-intolerant due to myopathy and need LDL lowering
• You are post-menopausal with a rising LDL that crossed the treatment threshold after menopause
• Blood pressure is already controlled

Losartan Is the Stronger Choice When:

• Your primary cardiometabolic driver is hypertension (stage 1 or 2)
• You have diabetic kidney disease or CKD with proteinuria
• You had an ACE inhibitor-induced cough (particularly relevant because this side effect is more common in women)
• You have heart failure with reduced ejection fraction as part of combination therapy
• LDL is at goal on current therapy

When Both May Be Appropriate:

A post-menopausal woman with type 2 diabetes, prior MI, blood pressure of 148/92 mmHg, and LDL of 82 mg/dL on high-intensity rosuvastatin may appropriately be on both losartan for blood pressure and kidney protection, and alirocumab for residual ASCVD risk reduction. These are not competing drugs. They work on separate pathways.

Cost, Access, and Practical Considerations

Losartan is generic, widely available, and costs under $15 per month at most pharmacies without insurance. Alirocumab requires prior authorization from most insurers and without coverage may cost over $500 per month, though Sanofi's patient assistance program (MySanofi) provides access for qualifying patients. The practical bar for starting alirocumab is therefore higher, which is one reason women with borderline ASCVD risk may be undertreated with PCSK9 inhibitors compared with similarly situated men.

Women are less likely than men to be prescribed PCSK9 inhibitors after an acute coronary syndrome, even when they meet guideline criteria. This disparity is documented in registry data and reflects both prescriber hesitancy and the lower representation of women in cardiovascular outcomes trials that generate guideline recommendations. Knowing this gap exists gives you a starting point for a more specific conversation with your cardiologist or primary care provider.

Monitoring: What to Track and When

Monitoring Alirocumab

• Fasting lipid panel 4 to 8 weeks after initiation or dose adjustment
• If LDL does not fall by at least 30% from baseline, reassess adherence to injection technique and statin background
• No routine hepatic or renal monitoring is required by the prescribing information
• Annual lipid reassessment once at goal

Monitoring Losartan

• Blood pressure at 2 to 4 weeks after initiation and after each dose change
• Basic metabolic panel (potassium, creatinine) at initiation and 1 to 2 weeks after starting, especially in women with CKD or those on diuretics
• Spot urine albumin-to-creatinine ratio annually in women with diabetes to assess renal protection
• Blood pressure goal in most women: <130/80 mmHg per the 2017 ACC/AHA Hypertension Guideline